![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1702369
¼¼°èÀÇ Ç³¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå(2025-2033³â)Global Balloon Valvuloplasty Devices Market - 2025-2033 |
Àü ¼¼°è dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå ±Ô¸ð´Â 2024³â 20¾ï 3,000¸¸ ´Þ·¯¿¡¼ 2033³â¿¡´Â 39¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ̸ç, ¿¹Ãø ±â°£ÀÎ 2025-2033³â¿¡´Â 6.8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â´Â ½ÉÀåÆÇ¸·ÀÇ ÇùÂøÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ÆÇ¸· ÀÔ±¸¸¦ ³ÐÇô Ç÷·ù¸¦ °³¼±Çϰí Áõ»óÀ» ¿ÏÈÇÕ´Ï´Ù. Áõ»ó ¿ÏÈ, ȸº¹ ½Ã°£ ´ÜÃà, ÀÔ¿ø ±â°£ ´ÜÃàÀ» ¸ñÀûÀ¸·Î ÁßÀçÀû ½ÉÀ庴Çп¡¼ ÀϹÝÀûÀ¸·Î »ç¿ëµË´Ï´Ù.
¼¼°è dz¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀåÀº ´ëµ¿¸ÆÆÇ¸· ÇùÂøÁõ, ½Â¸ðÆÇ¸· ÇùÂøÁõ, Æóµ¿¸ÆÆÇ Áúȯ°ú °°Àº ½ÉÀåÆÇ¸· ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àα¸ °í·ÉÈ¿Í °íÇ÷¾Ð, ´ç´¢º´, ºñ¸¸, Èí¿¬°ú °°Àº »ýȰ½À°ü °ü·Ã À§Çè¿äÀÎÀº ÀÌ·¯ÇÑ ÁúȯÀ» ´õ¿í ¾ÇȽÃ۰í ÀÖ½À´Ï´Ù. dz¼±ÆÇ¸· ¼ºÇü¼úÀº ¼ö¼úÀû ÆÇ¸· ġȯ¼úÀ» ´ëüÇÒ ¼ö ÀÖ´Â ÃÖ¼Òħ½ÀÀû Ä¡·á¹ýÀ¸·Î, ÀÔ¿ø ±â°£ ´ÜÃà, ȸº¹ ½Ã°£ ´ÜÃà, ¼ö¼ú ÈÄ ÇÕº´Áõ °¨¼Ò µîÀÇ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù.
¿¹¸¦ µé¾î, ½ÉÇ÷°ü°è ÁúȯÀÎ ½ÉÀåÆÇ¸·ÁõÀº Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, ±× Áß 4,100¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â ·ù¸¶Æ¼½º¼º ½ÉÀåÁúȯÀº °³¹ßµµ»ó±¹¿¡¼ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀþÀº ¼ºÀÎ Àα¸ÀÇ Áõ°¡¿Í Ç×»ýÁ¦, ¹Ì»ý¹°ÇÐÀû °Ë»ç, ½ÉÃÊÀ½ÆÄ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ °³¼±µÇ¾î Á¶±â »ç¸Á·üÀÌ ³·¾ÆÁ³±â ¶§¹®ÀÔ´Ï´Ù.
¼¼°è dz¼±ÆÇ¸·¼ºÇü¼ú ½ÃÀåÀº ÀçÇùÂø ¹× ±âŸ ½Ã¼ú ÇÕº´ÁõÀ¸·Î ÀÎÇÑ µµÀü¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀçÇùÂøÀº ½Ã¼ú ÈÄ Ä¡·áµÈ ÆÇ¸·ÀÌ ´Ù½Ã Á¼¾ÆÁö´Â °ÍÀ» ÀǹÌÇϸç, ÀÌ´Â Á¾Á¾ Àç¼ö¼úÀ» ÇÊ¿ä·Î Çϰí ȯÀÚ¿Í ÀÇ·á ½Ã½ºÅÛ¿¡ ºÎ´ãÀ» ÁÖ°Ô µË´Ï´Ù. À̴ ƯÈ÷ °í·ÉÀÇ È¯ÀÚ³ª ¼®È¸È°¡ ½ÉÇØ ½Ã¼ú È¿°ú°¡ ÀϽÃÀûÀÏ ¼ö Àִ ȯÀÚ¿¡¼ µÎµå·¯Áö°Ô ³ªÅ¸³³´Ï´Ù.
´Ù¸¥ À§ÇèÀ¸·Î´Â Ç÷°ü ÇÕº´Áõ, »öÀüÁõ, ºÎÁ¤¸Æ, ÆÇ¸· ¿ª·ù µîÀÌ ÀÖÀ¸¸ç, À̴ ȯÀÚÀÇ ¿¹Èĸ¦ ¾ÇȽÃų ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÕº´ÁõÀÇ °¡´É¼ºÀ¸·Î ÀÎÇØ ÀÇ·áÁøÀº ƯÈ÷ ¼ö¼úÀû ÆÇ¸· ġȯ¼ú°ú °°Àº ´õ ¿À·¡ Áö¼ÓµÇ´Â ´ëü Ä¡·á¹ýÀÌ ÀÖ´Â °æ¿ì, ÀÌ ½Ã¼úÀÇ ±¤¹üÀ§ÇÑ Ã¤ÅÃÀ» ÁÖÀúÇϰí ÀÖ½À´Ï´Ù. °æÇÇÀû ´ëµ¿¸Æ ÆÇ¸· ġȯ¼ú(TAVR)°ú °°Àº ´ëü Ä¡·á ¿É¼ÇÀÌ ÀÖ´Ù´Â Á¡µµ dz¼±ÆÇ¸·¼ºÇü¼ú ½ÃÀåÀÇ ¼ºÀåÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀÇ Ç³¼±ÆÇ¸·¼ºÇü¼ú ±â±â ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² Á¦Ç° À¯Çüº°, ¿ëµµº°, ¿¬·Éº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ, °æÀï ±¸µµ, ½ÃÀå ÁøÃâ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.
The global balloon valvuloplasty devices market reached US$ 2.03 billion in 2024 and is expected to reach US$ 3.95 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033.
Balloon valvuloplasty devices are medical devices used to treat valvular stenosis, a narrowing of heart valves. They widen the valve opening, improve blood flow, and reduce symptoms. They're commonly used in interventional cardiology for symptom relief, shorter recovery times, and reduced hospitalization duration.
Market Dynamics: Drivers & Restraints
Rising Prevalence of Valvular Heart Diseases
The global balloon valvuloplasty devices market is driven by the increasing prevalence of valvular heart diseases, such as aortic stenosis, mitral stenosis, and pulmonary valve disorders. The aging population and lifestyle-related risk factors like hypertension, diabetes, obesity, and smoking further exacerbate these conditions. Balloon valvuloplasty is a minimally invasive alternative to surgical valve replacement, offering benefits like shorter hospital stays, faster recovery times, and reduced post-operative complications.
For instance, valvular heart disease, a global cardiovascular disease, is increasing globally, with rheumatic heart disease, the most common, affecting 41 million people, increasing in developing nations. This is due to the growth of the young adult population and improved access to antibiotics, microbiological testing, and echocardiography, which have reduced premature mortality rates.
Risk of Restenosis and Procedural Complications
The global balloon valvuloplasty devices market faces challenges due to restenosis and other procedural complications. Restenosis, the re-narrowing of the treated valve after the procedure, often requires repeat interventions, burdening patients and healthcare systems. This is particularly evident in elderly patients or those with severe calcification, where the procedure's effectiveness may be temporary.
Other risks include vascular complications, embolization, arrhythmias, and valve regurgitation, leading to adverse patient outcomes. The potential for complications makes healthcare providers hesitant to adopt the procedure widely, especially when more durable alternatives like surgical valve replacement are available. The availability of alternative treatment options, such as transcatheter aortic valve replacement (TAVR), may also limit the growth of the balloon valvuloplasty devices market.
The global balloon valvuloplasty devices market is segmented based on product type, application, age group, end user, and region.
The standard balloon from product type segment is expected to dominate the balloon valvuloplasty devices market with the highest market share
Standard balloons are medical devices used in balloon valvuloplasty to dilate narrowed heart valves, restoring blood flow in patients with valvular stenosis. These high-strength balloons, available in various sizes and diameters, are delivered via catheter-based systems and inflated to break calcific deposits, improving valve function in high-risk patients not candidates for open-heart surgery.
The balloon valvuloplasty devices market is growing due to the increasing prevalence of valvular heart diseases, preference for minimally invasive procedures, technological advancements, expanding healthcare infrastructure, and government initiatives. Benefits include reduced hospital stays, faster recovery times, and fewer post-operative complications. Technological advancements and improved access to interventional cardiology in developing regions further support market growth.
North America is expected to hold a significant position in the balloon valvuloplasty devices market with the highest market share
The North American balloon valvuloplasty devices market is growing due to the increasing prevalence of valvular heart diseases, especially among the aging population. Technological advancements and favorable reimbursement policies are driving innovation. Increased awareness among healthcare professionals and patients, coupled with rising healthcare expenditure and government support for cardiovascular disease management, is expected to further accelerate market growth in North America.
For instance, in January 2025, Concept Medical has enrolled the first patient in its MAGICAL trial, comparing its sirolimus-coated balloon to traditional angioplasty for patients with below-the-knee PDA. The company secured an Investigational Device Exemption from the FDA for the MagicTouch PTA and is launching two more trials to evaluate its drug-coated alternative.
The major global players in the balloon valvuloplasty devices market include Medtronic, Balton, Boston Scientific Corporation, B. Braun Melsungen AG, Cardinal Health, Inc., Cook Medical Inc., Terumo Corporation, Becton, Dickinson and Company (BD), TORAY MEDICAL CO,.LTD., and BVM Medical, among others.
The global balloon valvuloplasty devices market report delivers a detailed analysis with 70 key tables, more than 74 visually impactful figures and 165 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
LIST NOT EXHAUSTIVE